Article info
PDFThursday 06 October 2022 from 13:00 to 14:10
PO.4 E- POSTER SESSION 4: disease activity measurements, flare and remission, epidemiology, etiology, genetics, epigenetics
PO.4.75 The anti-BDCA2 antibody biib059 improves joint and skin manifestations in patients with SLE and both active arthritis and rash
Citation
PO.4.75 The anti-BDCA2 antibody biib059 improves joint and skin manifestations in patients with SLE and both active arthritis and rash
Publication history
- First published September 27, 2022.
Online issue publication
October 13, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.